Filing Details

Accession Number:
0001562180-21-002835
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-15 17:53:19
Reporting Period:
2021-04-13
Accepted Time:
2021-04-15 17:53:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1560241 G1 Therapeutics Inc. GTHX Pharmaceutical Preparations (2834) 263648180
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1706847 A. Mark Velleca 700 Park Offices Drive, Suite 200
Research Triangle Park NC 27709
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-04-13 10,000 $0.39 51,000 No 4 M Direct
Common Stock Disposition 2021-04-13 10,000 $23.89 41,000 No 4 S Direct
Common Stock Acquisiton 2021-04-14 10,000 $0.39 51,000 No 4 M Direct
Common Stock Disposition 2021-04-14 10,000 $24.53 41,000 No 4 S Direct
Common Stock Acquisiton 2021-04-15 10,000 $0.39 51,000 No 4 M Direct
Common Stock Disposition 2021-04-15 10,000 $24.96 41,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2021-04-13 10,000 $0.00 10,000 $0.39
Common Stock Stock Options (Right to Buy) Disposition 2021-04-14 10,000 $0.00 10,000 $0.39
Common Stock Stock Options (Right to Buy) Disposition 2021-04-15 10,000 $0.00 10,000 $0.39
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
357,286 2024-05-09 No 4 M Direct
347,286 2024-05-09 No 4 M Direct
337,286 2024-05-09 No 4 M Direct
Footnotes
  1. This sale was effected pursuant to a Rule 10b5-1 trading plan.
  2. The price represents the weighted average price with a low of $23.68 and a high of $24.05. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
  3. The price represents the weighted average price with a low of $24.24 and a high of $24.81. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4.
  4. The price represents the weighted average price with a low of $24.62 and a high of $25.33. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4.
  5. All shares underlying this option have vested.